Stephanie Y Chen1, Aisling Last1, Abhinav Ettyreddy1, Dorina Kallogjeri1, Benjamin Wahle1, Smrithi Chidambaram2, Angela Mazul3, Wade Thorstad4, Ryan S Jackson1, Jose P Zevallos1, Patrik Pipkorn5. 1. Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA. 2. Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA; St. Louis University School of Medicine, St. Louis, MO, USA. 3. Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. 4. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA. 5. Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: ppipkorn@wustl.edu.
Abstract
OBJECTIVES: While smoking is associated with worse outcomes in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), the magnitude of this association is unclear given the heterogenous smoking definitions and outcomes. Our objective was to investigate the association between smoking, survival, and recurrence in HPV-related OPSCC using multiple smoking metrics reported in the literature. MATERIALS AND METHODS: This was a retrospective cohort study of 375 adults with p16+ OPSCC undergoing surgical resection (n = 272) or definitive chemoradiation (n = 103) at a tertiary academic institution from 2006 to 2017. The primary outcome was overall survival (OS). Secondary outcomes included disease-free survival (DFS), disease-specific survival (DSS), and recurrence. We used multiple smoking metrics commonly cited in previous studies, including ever versus never smokers, current versus former/never smokers, ≤10 versus >10 pack-year, ≤20 versus >20 pack-year, and continuous pack-year. RESULTS: There were 375 patients, median age 58 years, with 326 (87%) males, and median follow-up of 52 months. Of all smoking metrics, >20 pack-year history was the strongest predictor of both OS (HR 2.24, 95% CI: 1.19-4.20) and DFS (HR 1.67, 95% CI: 1.04-2.66) on univariable and multivariable analysis after adjusting for age, overall stage, and comorbidities. Patients with >20 pack-year smoking history were also more likely to have recurrence (HR 1.59, 95% CI: 0.95-2.67) after adjusting for overall stage. CONCLUSION: Heavier smoking >20 pack-years was the strongest smoking metric associated with 2-times worse survival and recurrence. Our findings suggest that >20 pack-year smoking history may be a more useful cutoff for risk stratification models but requires further validation.
OBJECTIVES: While smoking is associated with worse outcomes in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), the magnitude of this association is unclear given the heterogenous smoking definitions and outcomes. Our objective was to investigate the association between smoking, survival, and recurrence in HPV-related OPSCC using multiple smoking metrics reported in the literature. MATERIALS AND METHODS: This was a retrospective cohort study of 375 adults with p16+ OPSCC undergoing surgical resection (n = 272) or definitive chemoradiation (n = 103) at a tertiary academic institution from 2006 to 2017. The primary outcome was overall survival (OS). Secondary outcomes included disease-free survival (DFS), disease-specific survival (DSS), and recurrence. We used multiple smoking metrics commonly cited in previous studies, including ever versus never smokers, current versus former/never smokers, ≤10 versus >10 pack-year, ≤20 versus >20 pack-year, and continuous pack-year. RESULTS: There were 375 patients, median age 58 years, with 326 (87%) males, and median follow-up of 52 months. Of all smoking metrics, >20 pack-year history was the strongest predictor of both OS (HR 2.24, 95% CI: 1.19-4.20) and DFS (HR 1.67, 95% CI: 1.04-2.66) on univariable and multivariable analysis after adjusting for age, overall stage, and comorbidities. Patients with >20 pack-year smoking history were also more likely to have recurrence (HR 1.59, 95% CI: 0.95-2.67) after adjusting for overall stage. CONCLUSION: Heavier smoking >20 pack-years was the strongest smoking metric associated with 2-times worse survival and recurrence. Our findings suggest that >20 pack-year smoking history may be a more useful cutoff for risk stratification models but requires further validation.
Authors: Carmen P Liskamp; Geert O Janssens; Johan Bussink; Willem J Melchers; Johannes H Kaanders; Cornelia G Verhoef Journal: Head Neck Date: 2016-06-01 Impact factor: 3.147
Authors: Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Francis P Worden; Julia S Lee; Avraham Eisbruch; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jonathan B McHugh; Susan G Urba; Jay Stoerker; Heather M Walline; David M Kurnit; Kitrina G Cordell; Samantha J Davis; Preston D Ward; Carol R Bradford; Thomas E Carey Journal: Clin Cancer Res Date: 2010-02-09 Impact factor: 12.531
Authors: Jeanne L Hatcher; Katherine R Sterba; Janet A Tooze; Terry A Day; Matthew J Carpenter; Anthony J Alberg; Christopher A Sullivan; Nora C Fitzgerald; Kathryn E Weaver Journal: Head Neck Date: 2015-05-17 Impact factor: 3.147
Authors: Smrithi Chidambaram; Erik R Nakken; William Kennedy; Wade L Thorstad; Stephanie Y Chen; Patrik Pipkorn; Jose P Zevallos; Angela L Mazul Journal: Laryngoscope Date: 2020-04-15 Impact factor: 3.325
Authors: Alexis J Platek; Vijayvel Jayaprakash; Mihai Merzianu; Mary E Platek; David M Cohan; Wesley L Hicks; Sathiya P Marimuthu; Timothy B Winslow; Vishal Gupta; Hassan Arshad; Moni A Kuriakose; Shiva Dibaj; James R Marshall; Mary E Reid; Graham W Warren; Anurag K Singh Journal: Laryngoscope Date: 2016-06-27 Impact factor: 3.325
Authors: Maura L Gillison; Qiang Zhang; Richard Jordan; Weihong Xiao; William H Westra; Andy Trotti; Sharon Spencer; Jonathan Harris; Christine H Chung; K Kian Ang Journal: J Clin Oncol Date: 2012-05-07 Impact factor: 44.544
Authors: Angela M Hong; Andrew Martin; Mark Chatfield; Deanna Jones; Mei Zhang; Bruce Armstrong; C Soon Lee; Gerald Harnett; Christopher Milross; Jonathan Clark; Michael Elliott; Robert Smee; June Corry; Chen Liu; Sandro Porceddu; Guy Rees; Barbara Rose Journal: Int J Cancer Date: 2012-12-13 Impact factor: 7.396
Authors: Maura L Gillison; Keiko Akagi; David E Symer; Weihong Xiao; Bo Jiang; Robert K L Pickard; Jingfeng Li; Benjamin J Swanson; Amit D Agrawal; Mark Zucker; Birgit Stache-Crain; Anne-Katrin Emde; Heather M Geiger; Nicolas Robine; Kevin R Coombes Journal: Genome Res Date: 2018-12-18 Impact factor: 9.043
Authors: M M Rietbergen; B I Witte; E R Velazquez; P J F Snijders; E Bloemena; E J Speel; R H Brakenhoff; B Kremer; P Lambin; C R Leemans Journal: Br J Cancer Date: 2015-05-07 Impact factor: 7.640